Bipolar disorder (ICD-10 F31) is a serious mental illness characterised by episodes of extreme mood disturbance — swinging between periods of mania or hypomania (abnormally elevated or irritable mood, increased energy) and depressive episodes (low mood, loss of interest). Between episodes, mood may be relatively stable, or there may be a mix of symptoms.
Bipolar disorder affects approximately 1–2% of the population worldwide over a lifetime. It typically emerges in late adolescence or early adulthood and is a lifelong condition. Without treatment, episodes tend to recur and may worsen over time. With appropriate management — including mood stabilisers and psychological therapy — many people achieve long periods of stability.
ICD-10 recognises several distinct categories under the F31 Bipolar affective disorder umbrella:
- Bipolar I disorder — defined by at least one full manic episode (F31.1 without psychosis, F31.2 with psychotic features); depressive episodes are common but not required for diagnosis
- Bipolar II disorder — characterised by recurrent depressive episodes plus at least one hypomanic episode (F31.0); full mania is absent, which can make it harder to diagnose
- Cyclothymia (F34.0) — a milder, chronic form with repeated periods of mild elation and mild depression over at least 2 years; does not meet the full criteria for bipolar I or II
- Bipolar disorder, unspecified — used when the pattern does not fit neatly into the above types
ICD-10 also codes for the current episode type within F31 (e.g. F31.3 mild/moderate depression, F31.6 mixed state), allowing clinicians to specify the phase a patient is currently in.
Both bipolar disorder and unipolar depression (ICD-10 F32–F33) feature depressive episodes with low mood, fatigue, and loss of interest. The key difference is that bipolar disorder also involves periods of mania or hypomania — something that does not occur in unipolar depression.
This distinction matters because the treatment differs significantly. Antidepressants alone can be harmful in bipolar disorder — they may trigger a manic episode, a mixed state, or rapid cycling. NICE recommends a mood stabiliser as the foundation of bipolar treatment. Misdiagnosis as unipolar depression is common, particularly in Bipolar II where hypomania may be subtle or go unrecognised by both patient and clinician.
Bipolar disorder (F31) and EUPD/BPD (F60.31) can look similar — both involve mood instability, impulsivity, and interpersonal difficulties. The key clinical distinctions are:
- Duration of mood shifts: Bipolar episodes last days to months; EUPD mood swings can cycle within minutes to hours and are usually triggered by interpersonal events
- Trigger pattern: Bipolar episodes can arise endogenously (without a clear external cause); EUPD mood shifts are typically reactive to perceived abandonment, rejection, or criticism
- Identity disturbance: Core to EUPD (unstable self-image, chronic emptiness); not a defining feature of bipolar disorder
- Psychotic features: Can occur in bipolar mania (F31.2); in EUPD, transient quasi-psychotic states occur under stress but are brief
Both conditions can co-exist and careful longitudinal assessment is essential. Misdiagnosis is common in both directions.
Yes. Bipolar disorder is classified as a serious mental illness (SMI) in UK health policy. It significantly impacts a person's ability to function in daily life, maintain employment, and sustain relationships. Without treatment, the natural course of bipolar disorder involves recurrent episodes that typically worsen in frequency and severity over time — a pattern described by the kindling hypothesis.
The condition carries a substantial risk of suicide: people with bipolar disorder are estimated to have a lifetime suicide risk 15–20 times higher than the general population. Hospitalisation rates are high, particularly during acute manic or severely depressive episodes. However, with consistent treatment and support, many people live full and productive lives. Early diagnosis and intervention significantly improve long-term outcomes.
Bipolar disorder most commonly emerges in late adolescence to mid-20s. The average age of onset is approximately 25 years, though the first episode may occur earlier or later. Bipolar I disorder tends to present slightly earlier than Bipolar II.
Onset can occur in childhood (paediatric bipolar disorder is recognised but controversial and may present differently, with more rapid cycling and irritability than classic adult mania) and in older adults (late-onset bipolar can be associated with neurological conditions). Because early symptoms are often depressive — and the first manic or hypomanic episode may not occur until years later — the average time from symptom onset to correct diagnosis can be 6–10 years, during which misdiagnosis with unipolar depression is common.
ICD-10 (F31.1/F31.2) defines a manic episode as a distinct period of abnormally and persistently elevated, expansive, or irritable mood lasting at least 7 days. During this period, three or more of the following symptoms are present to a significant degree:
- Decreased need for sleep (feeling rested after only 3 hours)
- Inflated self-esteem or grandiosity (unrealistic belief in special powers, abilities, or importance)
- Racing thoughts or flight of ideas
- Pressured speech — more talkative than usual, difficulty being interrupted
- Distractibility — attention easily drawn to irrelevant stimuli
- Increased goal-directed activity (socially, at work, sexually) or physical agitation
- Reckless behaviour with high potential for harm — spending sprees, sexual indiscretions, poor business decisions
The severity must be sufficient to cause marked impairment in social or occupational functioning, or to require hospitalisation to prevent harm to the person or others.
Mania (F31.1/F31.2) is a severe episode of elevated or irritable mood that causes significant functional impairment and often requires hospitalisation. It lasts at least 7 days and may include psychotic features (F31.2).
Hypomania (F31.0) shares the same qualitative mood change but is milder. The key distinctions:
- Duration: Hypomania typically lasts at least 4 days (versus ≥7 for mania)
- Severity: Hypomania does not cause marked functional impairment — the person can still work and maintain relationships; mania does
- Psychosis: Hypomania does not include psychotic features; mania may (F31.2)
- Hospitalisation: Mania often requires hospitalisation; hypomania typically does not
People in a hypomanic state may actually feel unusually productive, creative, and sociable — which is why hypomania can go unrecognised or even be welcomed. This makes Bipolar II harder to diagnose, as patients often present only during depressive phases and may not volunteer information about previous "good" periods.
Yes. ICD-10 F31.2 specifically codes for a manic episode with psychotic features. Psychotic symptoms in mania are typically mood-congruent — meaning they fit the elevated mood state:
- Grandiose delusions — believing one has a special mission, is famous, or has extraordinary powers
- Persecutory delusions — believing others are trying to stop the person's "special work"
- Auditory hallucinations — sometimes hearing voices confirming the person's grandiosity
It is important to distinguish manic psychosis from schizophrenia (F20). In bipolar manic psychosis, the psychotic symptoms are time-limited to the episode and resolve when the mood episode resolves. Longitudinal history of mood episodes, family history, and full remission between episodes all support a bipolar diagnosis. Schizophrenia involves persistent psychosis not tied to mood episodes.
ICD-10 requires that a full manic episode lasts at least 7 days. In practice, untreated manic episodes commonly last weeks to months. Historically, before effective mood stabilisers were available, manic episodes lasted an average of 4–6 months. With modern treatment, episodes can be shortened significantly — often to days to weeks if medication is started promptly.
Hypomanic episodes (F31.0) are shorter, typically lasting 4 days to a few weeks. After a manic episode resolves, a depressive episode often follows (sometimes with only a brief euthymic interval), though this pattern is variable. Some people experience rapid switches from mania directly into depression — particularly dangerous because the suicidal ideation of depression arrives while the energy and impulsivity of mania are still present.
A mixed state (ICD-10 F31.6) is one of the most distressing and dangerous phases of bipolar disorder. It involves simultaneous manic and depressive symptoms — the person experiences the low mood, hopelessness, and suicidal ideation of depression combined with the energy, agitation, and impulsivity of mania.
People describe it as feeling "wired but exhausted," having racing thoughts about hopelessness and death, or feeling intensely agitated, restless, and unable to settle. The mixed state is considered the highest-risk period for suicide in bipolar disorder — because the person has the motivation and energy to act on suicidal thoughts, unlike in a pure depressive episode where psychomotor retardation may be protective. Mixed states are also particularly difficult to treat and require specialist assessment. Antidepressants can worsen or precipitate mixed states.
Common triggers for manic episodes include:
- Sleep deprivation — one of the most reliable and powerful triggers; even one night of poor sleep can precipitate hypomania in vulnerable individuals
- Psychosocial stress — major life events (positive or negative), relationship difficulties, work pressure
- Seasonal changes — mania more common in spring/summer; depression in autumn/winter for many people
- Substance use — stimulants (cocaine, amphetamines), cannabis, and even excessive caffeine can trigger episodes
- Antidepressant medication without a mood stabiliser — a well-documented risk per NICE guidelines
- Significant life changes — travel, new relationships, starting new projects
- Stopping mood stabilisers suddenly — particularly lithium, which carries a rebound mania risk
It depends on severity. During hypomania, many people are highly functional — often feeling unusually productive, creative, charismatic, and energetic. Some describe hypomania as the most enjoyable state they experience, which can make treatment adherence challenging (people may stop medication because they "miss" the hypomanic state).
During full mania (F31.1/F31.2), functioning is typically severely impaired. Poor judgement leads to reckless financial decisions, damaged relationships, dangerous behaviour, and often unsafe situations. Grandiosity means the person may not recognise their own impairment. Hospitalisation is often required — both to keep the person safe and to administer treatment they are unlikely to accept voluntarily during an acute manic episode.
Bipolar depression (F31.3–F31.5) and unipolar depression (F32–F33) share the core symptoms of low mood, anhedonia (loss of pleasure), fatigue, and concentration difficulties. The crucial difference is context: bipolar depression occurs in someone who has also experienced manic or hypomanic episodes — which dramatically changes the treatment approach.
Key reasons this distinction matters:
- Antidepressants alone are contraindicated in bipolar depression — they can trigger mania, mixed states, or rapid cycling without a mood stabiliser in place
- Bipolar depression tends to involve more hypersomnia, psychomotor slowing, and weight gain compared to the insomnia and agitation often seen in unipolar depression
- The suicide risk is higher in bipolar depression than in unipolar depression
- Bipolar depression often responds better to lithium (which has specific anti-suicidal properties) than to standard antidepressants
ICD-10 codes bipolar depressive episodes as F31.3 (mild/moderate) and F31.4/F31.5 (severe, without/with psychosis). Symptoms include:
- Persistent low mood — sadness, emptiness, or hopelessness most of the day, nearly every day
- Anhedonia — loss of interest or pleasure in activities previously enjoyed
- Fatigue and loss of energy — even small tasks feel exhausting
- Psychomotor retardation — slowed thinking, movement, and speech (more common in bipolar depression than unipolar)
- Hypersomnia — sleeping excessively, difficulty getting out of bed (often opposite to unipolar insomnia)
- Increased appetite and weight gain (again, often opposite to unipolar depression)
- Difficulty concentrating, indecisiveness
- Feelings of worthlessness or excessive guilt
- Recurrent thoughts of death or suicidal ideation
Bipolar depression presents several treatment challenges that do not apply to unipolar depression:
- Antidepressants can destabilise mood — using an antidepressant without a mood stabiliser risks precipitating a manic episode, a mixed state, or rapid cycling; NICE CG185 advises against antidepressant monotherapy in bipolar disorder
- Delayed recognition — patients (and clinicians) may not connect the depressive phase to a bipolar disorder, particularly if mania or hypomania was mild or occurred years earlier
- Response time — lithium's antidepressant effect can take weeks to build; the acute depressive episode may require other strategies in the interim
- Quetiapine (an atypical antipsychotic) is currently one of the most evidence-based pharmacological options for bipolar depression per NICE
Lithium retains its importance here: it is the only treatment consistently shown to have specific anti-suicidal properties in bipolar disorder, making it uniquely valuable when suicidality is present during bipolar depression.
Yes. ICD-10 F31.5 codes for a severe bipolar depressive episode with psychotic features. Psychosis in bipolar depression typically involves mood-congruent delusions consistent with the depressive state — for example:
- Delusions of guilt — believing one has committed a terrible crime or is responsible for catastrophe
- Nihilistic delusions — believing one is dead, that organs have failed, or that nothing exists
- Delusions of poverty — believing one has lost all money or possessions despite evidence to the contrary
- Auditory hallucinations — voices that are often accusatory or condemning
Psychotic depression within bipolar disorder requires urgent treatment — typically a combination of mood stabiliser and antipsychotic medication, with hospital admission often necessary. The presence of psychotic features significantly raises the suicide risk and requires careful risk assessment.
Depressive episodes in bipolar disorder are typically longer in duration than manic episodes. Untreated, a bipolar depressive episode averages approximately 13 weeks, though this varies widely. Some episodes resolve in a few weeks; others may persist for 6 months or longer without treatment.
Research consistently shows that people with bipolar disorder spend more time in depressive phases than in manic or hypomanic phases over the course of their illness — often by a ratio of 3:1 or more. This means that bipolar depression, not mania, is the dominant source of long-term disability, lost productivity, and reduced quality of life for most people with the condition. This underscores why effective treatment of bipolar depression is so clinically important.
Rapid cycling is defined as experiencing 4 or more distinct mood episodes per year — these episodes may be manic, hypomanic, or depressive. It is not a separate diagnosis but a course specifier that indicates a more severe illness course. Rapid cycling occurs in approximately 10–20% of people with bipolar disorder and is associated with a poorer prognosis, greater functional impairment, and higher suicide risk.
Key clinical points:
- More common in Bipolar II than Bipolar I
- More common in women than men
- Strongly associated with antidepressant use without a mood stabiliser — antidepressants can induce or worsen rapid cycling
- Thyroid dysfunction (hypothyroidism) is a recognised but treatable contributor
- Treatment is more challenging; lithium may be less effective alone; valproate, lamotrigine, or combination therapy may be required
Bipolar disorder varies considerably between individuals. Some general patterns include:
- Many people experience years of stability between episodes, particularly with good treatment adherence
- Episodes often have a seasonal component — mania and hypomania are more common in spring and summer; depression in autumn and winter
- Without treatment, episodes tend to become more frequent and severe over time — the kindling hypothesis suggests each episode lowers the threshold for future episodes
- Some people have predominantly depressive episodes with occasional hypomania (Bipolar II); others have more manic episodes (Bipolar I)
- Spontaneous remission can occur, but the disorder rarely resolves permanently without management
Long-term follow-up studies show that people with bipolar disorder are symptomatic (either manic, depressive, or mixed) for roughly half of their lifetime, making ongoing maintenance treatment essential.
Yes — psychosocial stress is one of the most well-established triggers for bipolar episodes. The kindling hypothesis provides a useful framework: early episodes are more likely to be triggered by significant external stressors, but over time the brain becomes increasingly sensitised, so that later episodes may occur with minimal or no discernible trigger.
Both positive and negative life events can trigger episodes. A stressful bereavement or relationship breakdown may precipitate a depressive episode; an exciting life change (a new relationship, a promotion, travel) can trigger hypomania or mania. The common factor is disruption to routine, sleep, and biological rhythms — which is why IPSRT (Interpersonal and Social Rhythm Therapy), a therapy that specifically targets sleep and routine stability, is recommended by NICE as a psychological treatment for bipolar disorder.
Sleep has a bidirectional relationship with bipolar disorder — it is both a key trigger and an early warning sign of episodes. Sleep disruption is one of the most powerful and consistent triggers for manic episodes. Even a single night of significantly reduced sleep can precipitate hypomania or mania in someone with bipolar disorder.
Conversely, changes in sleep are among the earliest warning signs of an impending episode:
- Reduced sleep need (feeling rested after 3–4 hours) — early warning of mania/hypomania
- Excessive sleep, difficulty getting up — early warning of depression
Maintaining a consistent sleep schedule — going to bed and waking at the same time daily, even at weekends — is one of the most effective self-management strategies for bipolar disorder. This is a core component of IPSRT and the basis of sleep hygiene psychoeducation in bipolar management.
Recognising personal early warning signs is a key part of relapse prevention in bipolar disorder. Warning signs are highly individual, but common patterns include:
For mania/hypomania:
- Needing less sleep but feeling unusually energised
- Increased talkativeness or feeling thoughts are racing
- Starting multiple new projects simultaneously
- Increased spending, socialising, or sexual interest
- Feelings of unusual confidence or specialness
For depression:
- Social withdrawal and reduced communication
- Loss of motivation for usual activities
- Changes in sleep (often too much) and appetite
- Negative, hopeless thinking returning
NICE recommends that people with bipolar disorder work with their care team to create a personal relapse signature — a written record of their unique early warning signs — to enable early intervention before a full episode develops.
Yes — substance use is strongly associated with worsening bipolar disorder. Research shows that rates of substance use disorders are significantly higher in people with bipolar disorder than in the general population, and the two conditions adversely interact:
- Alcohol — a CNS depressant that can destabilise mood, worsen depression, disrupt sleep, and interact with mood-stabilising medications (particularly dangerous with lithium and valproate)
- Cannabis — associated with psychotic episodes in bipolar disorder; use is linked to earlier onset, more episodes, and worse outcomes
- Stimulants (cocaine, MDMA, amphetamines) — can directly trigger manic episodes and significantly worsen the course of bipolar disorder
Substance use also undermines treatment adherence — people who use substances are less likely to take medication consistently. NICE recommends that substance use be assessed and addressed as part of a comprehensive bipolar disorder management plan.
Yes — this is a well-established clinical concern. NICE CG185 explicitly cautions that antidepressants used without a mood stabiliser in bipolar disorder can:
- Trigger a manic episode — antidepressants can "switch" a person from depression into mania or hypomania
- Induce mixed states — which carry the highest suicide risk in bipolar disorder
- Worsen or precipitate rapid cycling — increasing the frequency of mood episodes overall
For this reason, NICE recommends that when treating bipolar depression, the first step is to optimise or introduce a mood stabiliser (such as lithium or quetiapine), not to add an antidepressant. If an antidepressant is used at all, it should only be in combination with a mood stabiliser and with careful monitoring. This distinction is a major reason why correct diagnosis of bipolar disorder (versus unipolar depression) is so important before commencing treatment.
No single cause explains bipolar disorder. Research points to a biopsychosocial model — a combination of genetic, neurobiological, and environmental factors:
- Genetic factors — bipolar disorder is one of the most heritable psychiatric conditions (see below); multiple genes of small effect contribute to risk
- Neurobiological factors — abnormal regulation of neurotransmitters (dopamine, serotonin, noradrenaline) and dysregulation of circadian rhythm systems are central to the illness; the suprachiasmatic nucleus and melatonin pathways are implicated
- Environmental triggers — stressful life events, sleep disruption, substance use, and major life changes can trigger the first episode in genetically vulnerable individuals
- Psychosocial factors — childhood adversity, trauma, and chronic stress do not cause bipolar disorder but can influence the timing and severity of onset
The interaction between a biological vulnerability (genetic/neurobiological predisposition) and environmental triggers is the most widely accepted explanatory model.
Bipolar disorder has a strong genetic component. Twin studies estimate heritability at approximately 60–80% — among the highest of any psychiatric condition. First-degree relatives (parents, siblings, children) of someone with bipolar disorder have approximately 10 times the population risk of developing it themselves.
Genome-wide association studies (GWAS) have identified variants in several genes associated with increased risk, including CACNA1C (a calcium channel gene also implicated in schizophrenia) and ANK3. However, bipolar disorder is not a single-gene disorder — it arises from the interaction of many genetic variants of small individual effect, combined with environmental factors. Having a family member with bipolar disorder increases risk but does not determine outcome.
The main risk factors associated with developing bipolar disorder include:
- Family history — the single strongest risk factor; having a first-degree relative with bipolar disorder increases risk approximately 10-fold
- Childhood adversity and trauma — strongly associated with earlier onset and a more severe illness course
- Substance misuse — particularly cannabis and stimulants; may trigger the first episode in genetically vulnerable individuals
- Chronic sleep disruption — sustained disruption to circadian rhythms (e.g. shift work, chronic insomnia) increases vulnerability
- Major stressful life events — can precipitate the first episode
- Possible inflammatory and immune factors — emerging research suggests dysregulation of inflammatory pathways may contribute, though this is not yet established clinically
Yes — neuroimaging studies consistently show structural and functional brain differences in people with bipolar disorder compared to the general population. Key findings include:
- Reduced grey matter in the prefrontal cortex — an area critical for emotion regulation, impulse control, and decision-making
- Enlarged amygdala activity — the brain's threat and emotion-processing centre shows heightened responses to emotional stimuli
- Hippocampal changes — volume reductions in some studies, potentially related to the stress-response effects of repeated mood episodes
- White matter abnormalities — disruptions in connectivity between brain regions involved in mood regulation
These findings are correlates of the condition — not diagnostic markers. There is currently no brain scan or blood test that can diagnose bipolar disorder. Diagnosis remains clinical, based on history and mental state examination.
Trauma does not directly cause bipolar disorder in the way it causes PTSD, but there is a strong association between childhood adversity and bipolar disorder. Research shows that people with bipolar disorder who experienced childhood trauma tend to have:
- Earlier onset of the illness
- A more severe course with more frequent episodes
- Greater suicidality and self-harm
- Higher rates of comorbid conditions (PTSD, substance use, anxiety)
Clinically, distinguishing bipolar disorder from Complex PTSD (ICD-11 6B41) is important — both can present with mood instability, impulsivity, and interpersonal difficulties. However, Complex PTSD centres on a trauma narrative and features dissociation, shame, and negative self-concept in response to prolonged trauma, whereas bipolar disorder's mood episodes often arise independently of specific triggers and involve the classic mania/hypomania polarity.
Bipolar disorder affects people across all demographics, with some notable patterns:
- Sex: Bipolar I disorder affects men and women equally; Bipolar II disorder is slightly more common in women
- Women are also more prone to rapid cycling, mixed states, and more depressive episodes relative to manic episodes
- Ethnicity: No clear ethnic variation in prevalence is established when socioeconomic factors are controlled; however, some studies suggest Black and minority ethnic groups are more likely to be misdiagnosed (particularly with schizophrenia rather than bipolar disorder) due to systemic biases in psychiatric assessment
- Socioeconomic status: Bipolar disorder is associated with higher rates of unemployment, financial difficulty, and social isolation — though it is unclear how much is cause versus consequence
Bipolar disorder requires long-term, integrated management combining pharmacological treatment with psychological support. NICE CG185 provides the UK clinical framework:
- Mood stabilisers — the cornerstone of long-term maintenance treatment to prevent future episodes
- Acute treatment — different approaches for managing manic, depressive, and mixed episodes as they occur
- Psychological therapies — CBT adapted for bipolar, IPSRT, psychoeducation, and family therapy alongside medication
- Care coordination — most people with bipolar disorder benefit from a named care coordinator (often a CPN) and an agreed crisis plan
Treatment has two phases: acute (managing the current episode) and maintenance (preventing future episodes). Long-term adherence to maintenance treatment is critical — the majority of relapses occur when medication is stopped or doses are missed.
The main medication groups used in bipolar disorder include:
- Lithium — gold-standard long-term mood stabiliser; first-line for maintenance per NICE; also has anti-suicidal properties; requires regular blood monitoring
- Valproate (valproic acid/sodium valproate) — effective mood stabiliser, particularly for mania and rapid cycling; contraindicated in women of childbearing age due to teratogenicity (MHRA guidance 2018/2024)
- Lamotrigine — particularly effective for the depressive phase; NICE-recommended for bipolar depression prevention; slower titration needed
- Atypical antipsychotics: quetiapine (effective for both phases; first-line for bipolar depression), olanzapine, aripiprazole — used for acute mania and as maintenance
The choice of medication depends on the predominant episode polarity, the patient's history, comorbidities, and reproductive status. Regular medication reviews are essential.
Lithium is a naturally occurring element that has been used as a mood stabiliser since the 1950s. It remains the first-line long-term treatment for bipolar disorder according to NICE CG185. Its mechanisms of action are not fully understood but involve modulation of neurotransmitter systems (serotonin, dopamine) and neuroprotective effects on brain cells.
Key clinical properties of lithium:
- Reduces the frequency and severity of both manic and depressive episodes
- Has well-documented anti-suicidal properties — one of only a handful of medications with evidence of reducing suicide risk specifically
- Requires regular blood monitoring to maintain a therapeutic serum level (typically 0.6–1.0 mmol/L for maintenance; toxic above 1.5 mmol/L)
- Kidney and thyroid function must be monitored regularly — long-term lithium use can affect both
- Hydration is critical — lithium levels rise dangerously when fluid intake is reduced (illness, hot weather, exercise)
NICE CG185 recommends several evidence-based psychological therapies for bipolar disorder, always in addition to (not instead of) medication:
- Cognitive Behavioural Therapy (CBT) adapted for bipolar — addresses negative thinking patterns, helps monitor mood, and develops coping strategies
- Psychoeducation — structured education about bipolar disorder, triggers, early warning signs, and treatment; one of the most cost-effective interventions and reduces relapse rates significantly
- Interpersonal and Social Rhythm Therapy (IPSRT) — specifically targets sleep and daily routine disruption, the most common trigger for episodes; helps establish stable circadian rhythms
- Family-focused therapy — involves close family members or partners; improves communication, reduces expressed emotion, and educates the family system
- Group therapy and peer support — Bipolar UK offers peer support groups; reducing isolation and normalising experience is therapeutically valuable
There is currently no cure for bipolar disorder — it is a lifelong condition. However, this does not mean it cannot be managed very effectively. Many people with bipolar disorder achieve long periods of stability — months or even years — during which they live full, productive lives indistinguishable from people without the condition.
The goal of treatment is not cure but remission and relapse prevention: reducing the frequency, severity, and impact of episodes; maintaining stable functioning between episodes; and preserving quality of life. Consistent medication adherence, psychological therapies, lifestyle management (sleep, routine, substance avoidance), and good social support are the foundations of long-term wellbeing with bipolar disorder.
Untreated bipolar disorder typically follows a worsening trajectory over time. The consequences of no treatment include:
- Increasing episode frequency and severity — the kindling hypothesis predicts that each episode lowers the threshold for future episodes; early treatment may slow this process
- Elevated suicide risk — lifetime suicide risk in untreated bipolar disorder is estimated at 15–20 times the general population; risk is highest during mixed states and severe depression
- Relationship damage — manic episodes frequently cause lasting harm to relationships, financial standing, and professional reputation through impulsive behaviours the person later regrets
- Occupational impairment — recurrent episodes disrupt employment; untreated bipolar disorder is associated with high rates of disability
- Substance misuse — self-medication with alcohol or drugs is common without treatment, creating an additional clinical problem
- Cognitive decline — some evidence suggests repeated mood episodes have cumulative effects on cognitive function
Yes — many people with bipolar disorder lead full, productive, and meaningful lives. The condition requires consistent management, but it does not define a person's potential. Several high-profile public figures have spoken openly about living with bipolar disorder, including Stephen Fry, Mariah Carey, Carrie Fisher, Kay Redfield Jamison (a psychiatrist and bipolar disorder expert who wrote extensively about her own experience), and Brian Wilson (of The Beach Boys).
Success requires a combination of: consistent treatment adherence (medication and therapy), self-awareness (recognising early warning signs), a stable routine (particularly sleep), a supportive social network, and often a collaborative care team. With these foundations in place, many people with bipolar disorder sustain long-term careers, relationships, and families.
Bipolar disorder can place significant strain on relationships. During manic episodes, the person may become irritable, make impulsive decisions, spend recklessly, have increased sexual energy, or say and do things they later regret. Partners and family members may feel frightened, helpless, or overwhelmed. During depressive episodes, withdrawal, hopelessness, and low functioning can leave loved ones feeling shut out.
Fear of abandonment is common during depressive phases; during mania, the person may not see why others are concerned. Open communication is essential — during stable periods, couples or families can discuss what bipolar looks like for that person, agree on roles during episodes, and discuss what is (and is not) helpful. Psychoeducation for partners and family significantly improves outcomes. Bipolar UK offers resources specifically for families and carers.
A relapse prevention plan (also called a wellness recovery action plan or advance statement) is a personal document developed collaboratively with a care team that helps the person and their support network recognise and respond early to signs of a new episode. NICE recommends that all people with bipolar disorder have an agreed crisis plan.
A comprehensive plan typically includes:
- Personal early warning signs for mania and depression (unique to each individual)
- Known triggers to avoid or manage (sleep disruption, stress, substances)
- Crisis contacts — named care coordinator, GP, emergency contact
- Steps to take at each stage of escalating symptoms
- Medication guidance — what to do if a dose is missed, or if symptoms worsen
- An advance statement — preferences for care if the person loses capacity during a manic episode
Supporting someone during a manic episode can be challenging. Key principles:
- Stay calm — agitation is contagious; a calm, warm demeanour helps de-escalate
- Do not argue with or challenge grandiose beliefs directly — this typically escalates distress without changing the person's mind
- Remove access to risks if safe to do so — car keys, credit cards, internet banking — if impulsive spending or driving is a concern
- Encourage sleep — gently suggest resting; sleep deprivation worsens mania rapidly
- Contact their care team — if they have a Community Mental Health Team, CPN, or crisis team, make early contact; don't wait until the situation is dangerous
- Safety first — if there is immediate risk to the person or others, call 999; if urgent but not immediately dangerous, call NHS 111 option 2
Supporting someone through a bipolar depressive episode requires patience, consistency, and care. Helpful approaches include:
- Maintain contact — low-key, regular contact (a text, a short visit) reduces isolation; don't interpret withdrawal personally
- Don't minimise or offer simple solutions — saying "just get outside" or "you have so much to be grateful for" is invalidating; acknowledge how hard things are
- Encourage professional help — gently support them to contact their care team or GP if they haven't; offer to help make a call or attend an appointment
- Watch for suicidal signs — if they express suicidal thoughts or plans, take it seriously; ask directly ("Are you thinking about suicide?"); contact their crisis team or call 999
- Help maintain routine — small, structured activities (a short walk, a regular meal) provide anchors during depression
Bipolar disorder can significantly affect work — but many people with the condition work successfully, particularly with the right support and adjustments. During depressive episodes, concentration, motivation, and reliability may be severely impaired. During manic episodes, poor judgement and impulsivity can cause workplace difficulties, damaged professional relationships, or disciplinary issues the person later regrets.
Key considerations for employment:
- Disclosure is a personal choice; there is no legal obligation to disclose in the UK; however, disclosure enables access to reasonable adjustments
- Under the Equality Act 2010, bipolar disorder typically qualifies as a disability; employers are legally required to make reasonable adjustments
- Common adjustments: flexible start times (to accommodate medication side effects or poor sleep), reduced workload during recovery, ability to work from home, mental health days
- Some occupations (HGV driving, certain medical roles, armed forces) may impose restrictions — these are reviewed on a case-by-case basis
Several routes to support are available in the UK:
- Your GP — first point of contact; can refer to Community Mental Health Team (CMHT), psychiatrist, or talking therapies
- Community Mental Health Team (CMHT) — provides ongoing care coordination, medication review, CPN (community psychiatric nurse) support
- Crisis support: call 999 (emergency), NHS 111 option 2 (urgent mental health), or Samaritans 116 123 (24/7, free, confidential)
- Mind — mind.org.uk — information, local Mind services, peer support
- Rethink Mental Illness — rethink.org — advice line, carer support, advocacy
- Bipolar UK — bipolaruk.org — specialist bipolar charity; peer support groups, helpline, resources for carers
- NICE guideline CG185 (Bipolar Disorder in Adults) — evidence-based treatment guidance for clinicians and patients
No results found
Try a different search term, or .